



The ISFA wishes to acknowledge the following 2014 Corporate Sponsors

ASAHI KASEI MEDICAL CO., LTD.

Asahi Kasei Medical Co., Ltd. (Tokyo, Japan) is a world leader in research, development, and production of devices and systems for blood treatment and purification based on advanced membrane separation and adsorption technologies. It serves the global market with dialysis products and therapeutic apheresis devices, such as membrane type plasma separators, plasma component separators, leukocytapheresis columns, and immunoabsorption columns. Asahi Kasei Medical's core competence is in blood related polymer technologies, materials technologies, and blood analysis technologies. The Research and Development Division is developing next-generation products based in these technologies for fields ranging from extracorporeal therapy to organ function diagnosis and artificial organs. Now, as always, Asahi Kasei Medical is dedicated to serving and advancing medical therapy for the preservation and enhancement of human life. **Company Website:** <http://www.asahikasei-medical.com>

JIMRO

JIMRO Co., Ltd. (Gunma, Japan) developed the Adacolumn as the world's first selective granulocyte and monocytes/macrophage apheresis system. The selectivity of this product ensures that most lymphocytes are spared as the majority of cytokines they produce have vital roles for efficient immune function. Adacolumn is filled with specially designed cellulose acetate beads as adsorptive carriers which remove most granulocytes, monocytes/macrophages and a small fraction of lymphocytes (FcγR and complement receptor bearing leukocytes in the column) from the blood. Adacolumn is approved by the Ministry of Health, Labour and Welfare in Japan for public funding in the treatment of patients with ulcerative colitis. Adacolumn is currently CE-Marked (validated) by TUV of Germany for rheumatoid arthritis, ulcerative colitis, Crohn's disease, ocular Behcet's disease, and systemic lupus erythematosus. Accordingly, Adacolumn is available in the EU for the treatment of these conditions. We have started the 21st century with a renewed determination to continue our efforts to develop innovative products. Our ultimate goal is to provide effective challenges against refractory diseases worldwide. **Company Website:** <http://www.jimro.com/>

Kaneka

Kaneka Corporation (Osaka and Tokyo, Japan) is a global chemical company. Our technologies create products and services that make a worldwide contribution in harmony with the environment. We especially focus on the life science field, such as medical devices, fine chemicals and functional foods. In the field of medical devices, Kaneka has been pursuing the development of a unique system to be used particularly in plasmapheresis, targeting refractory diseases that are hard to cure by conventional therapies. High cholesterol levels in plasma are known to be one of the major risk factors causing coronary heart diseases such as myocardial infarction. Liposorber is a highly selective LDL-adsorption column developed by Kaneka, capable of lowering plasma cholesterol to the desired level. Kaneka is the first company in the world to have started manufacturing this type of adsorption column on an industrial scale. Since its introduction into the market in 1986, our LDL-apheresis system, which combines Liposorber and Sulflux (a

membrane-type plasma separator), has been enjoying an excellent reputation in the medical community. Following these achievements, Kaneka commercialized Selesorb, a selective adsorption column for the treatment of systematic lupus erythematosus, and Lixelle for the treatment of dialysis-related amyloidosis. **Company Website:** <http://www.kaneka.co.jp/> or <http://www.liposorber.com/>

KAWASUMI LABORATORIES, INC.

Kawasumi Laboratories, Inc. (Tokyo, Japan) is a pioneer of dialyzer and devices for blood collection and transfusion in Japan. Kawasumi is one of the leading companies in the hemodialysis field. The company's major products for hemodialysis include dialyzers, blood tubing lines, and arterial venous fistula needles. These products have maintained high market share in the world. Kawasumi is also one of the leading manufacturers in the blood banking field. The main products related to blood banking are blood bags, apheresis kits for separating/collecting plasma and platelet in blood donation, and the leukocyte removal filter which removes leukocytes that cause side effects to patients in blood transfusion. These products have received worldwide recognition because of their high quality. Also, Kawasumi is focused on developing products for tissue engineering such as guided bone regeneration membrane and intervention including coronary stents and stent grafts for cardiovascular diseases. Kawasumi has a large production base in Japan and Thailand. In the United States, the company has a distribution base which is important for both markets in North and South America. Kawasumi is a global company with a network for distribution worldwide. **Company Website:** <http://www.kawasumi.jp/>

NIKKISO

Nikkiso Co., Ltd. (Tokyo, Japan). **Nikkiso Co., Ltd.** (Tokyo, Japan). In 1959, Nikkiso was commissioned by the Kimoto Surgical Department of the University of Tokyo to develop Japan's first artificial heart. The successful introduction of this product was the starting point for Nikkiso's medical operations. This early success was followed by Nikkiso's introduction in 1969 of Japan's first hemodialysis system. Since then, Nikkiso has remained at the forefront of dialysis technology. Our excellent reputation for reliable equipment and customer service has enabled us to become one of the world's largest manufacturers of hemodialysis equipment. Nikkiso has expanded its products including the world's only commercial artificial pancreas. In overseas markets, Nikkiso mainly provides products to European and Asian countries. Our hemodialysis products include hemodialysis systems hollow fiber dialyzers, and blood tubing lines. Other medical products include infusion pumps, syringe pumps, and osmometers. Nikkiso continues to apply its technological leadership to the improvement and development of medical devices which contribute to the quality of life. **Company Website:** <http://www.nikkiso.co.jp/>

NIPRO

NIPRO Corporation (Osaka, Japan) currently offers total product lineup related to dialysis, high-function products starting with catheters which are essential to today's advanced level of medicine, a range of the most generally used disposable medical products in

each ward such as in nursing and testing, kit products which are the principal target of our cooperative development with various pharmaceutical companies, and a variety of glass products for medical and industrial use. In particular, we have put efforts into the development of many kinds of products which include hemodialyzers, machines, bloodlines, catheters, and dialysate for artificial kidneys. On the other hand, we have developed and offer many products for apheresis therapy, for example, blood bags and cord collection bags. We are continuing research in the areas of artificial organs and regenerative medicine. We have five major manufacturing bases and sales hubs around the world, centered in Europe, North and South America, and Asia. **Company Website:** <http://www.nipro.co.jp/>

'TORAY'

Toray Industries, Inc. (Tokyo, Japan). Since its founding, Toray stands ready to meet the challenges of the future by creating new technologies attuned to the changing times while expanding into new technological fields. In the medical device area, Toray has developed and marketed a number of unique and well-regarded products such as Toraymyxin and Hemofeel. Toraymyxin is a blood purification device consisting of polymyxin B-immobilized fiber which removes plasma endotoxin from septic patients thus improving their hemodynamics. Hemofeel is a hemofilter used mainly for adjusting the composition of body fluids of patients with acute renal failure receiving treatment in ICU and Emergency & Critical Care Department. Depending on the purpose of the treatment, you can choose between two types of filters, one is a high-flux

membrane made with polysulfone and the other is Hemofeel CH made with PMMA membrane for conditions where the removal of substances causing illness is important. **Company Website:** <http://www.toray.co.jp/>



TORII PHARMACEUTICAL CO., LTD.

Torii Pharmaceutical Co., Ltd. (Tokyo, Japan). During the more than 130 years since its founding, Torii Pharmaceutical Co., Ltd., has contributed to the improvement of human health by focusing on developing, producing, and distributing ethical pharmaceutical products. In 1998, Torii became a member of the Japan Tobacco Inc. (JT) Group. To maximally leverage the synergistic effects of the Group, R&D functions were transferred to JT and sales and marketing functions were transferred to Torii. These moves clarified the respective roles of Torii and JT, facilitating the creation of an efficient business structure that optimizes the respective strengths of both companies. Torii and JT continue to operate in close collaboration. **Company Website:** <http://www.torii.co.jp/>

For information on Corporate Sponsorship, Advertising, and Individual Membership, contact:

Yoshihiro Endo, M.D., PhD. Secretary Treasurer of ISFA

Department of Surgery, Shiga University of Medical Science

Seta Tsukinowa-cho, Otsu, Shiga 520-2192, Japan

FAX: +81-77-548-2240, E-mail: isfa@belle.shiga-med.ac.jp

Website: <http://www.shiga-med.ac.jp/~hqsurge1/ISFA.html>